Daliresp Oral Tablet 500Mcg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

DALIRESP: Oral tablet (500mcg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Daliresp 500mcg Tablet
Drug Image file default-drug-image.png
Daliresp 500mcg Tablet
Drug Image file DrugItem_14523.JPG
Daliresp 500mcg Tablet
Actavis- US Brands formerly Forest Pharmaceuticals Inc
Pill Identification: D  |  500
Drug Image file default-drug-image.png
Daliresp 500mcg Tablet

What is this Medicine?

ROFLUMILAST (roe FLUE mi last) decreases inflammation in the lungs. This medicine is used to prevent COPD flare-ups. Do not use this medicine to treat sudden breathing problems.

CVS Pharmacy Patient Statistics for DALIRESP: Oral tablet(500mcg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information
Select a Medication

Daliresp 500mcg Tablet

NDC: 003100095
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Chronic Obstructive Pulmonary Disease (COPD)

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Daliresp 500mcg Tablet

Reported Side Effects for Daliresp 500mcg Tablet

Thoughts Of Suicide Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Rhinitis Incidence:
1.0-2.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
1.0-2.0%*
Severity: MILD
Onset: EARLY
Muscle Cramps Incidence:
1.0-2.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
1.0-2.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
1.0-2.0%*
Severity: MILD
Onset: EARLY
Shaking Incidence:
1.0-2.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
1.0-2.0%*
Severity: MILD
Onset: DELAYED
Inflamed Stomach Incidence:
1.0-2.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
1.0-2.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
1.0-2.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
1.0-2.0%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
2.1%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
2.1%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
2.4%*
Severity: MILD
Onset: EARLY
Flu Incidence:
2.8%*
Severity: MILD
Onset: DELAYED
Back Pain Incidence:
3.2%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
4.4%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
4.7%*
Severity: MILD
Onset: EARLY
Weight Loss Incidence:
7.0-20.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
9.5%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Daliresp 500mcg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Alcohol and Daliresp 500mcg Tablet(Roflumilast)
Alcohol and Roflumilast(Roflumilast)
It is best to avoid alcohol-containing drinks while you are taking Roflumilast. Alcohol may decrease the actions of Roflumilast, making it less effective at treating your condition. If you have questions regarding this recommendation, talk to your health care provider.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with DALIRESP

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.